Others have indicated that a combination therapy of tamoxifen and potassium channel blockers may be important in treatment of breast cancer due to the effects of potassium channels on increasing breast cancer cell proliferation (Abdul et al. 2003). This evidence concerns the gene KCNA3 and breast carcinoma.